Celcuity (CELC) Assets Average (2017 - 2026)
Celcuity's (CELC) quarterly Assets Average came in at $471.3 million in Q4 2025, up 81.91% YoY from $259.1 million in Q4 2024, and up 42.9% on a QoQ basis from $329.8 million in Q3 2025.
Celcuity (CELC) Assets Average (2017 - 2026) Analysis & Trends
Celcuity (CELC) has 9 years of Assets Average data on file, last reported at $471.3 million in Q4 2025.
- Quarterly Assets Average rose 81.91% year-over-year to $471.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $471.3 million (up 81.91% YoY) and the FY2025 annual result came in at $355.8 million, up 63.1% from the prior year.
- Assets Average improved to $471.3 million in Q4 2025, from $329.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $471.3 million in Q4 2025 to a low of $24.7 million in Q1 2021.
- A 5-year average of $170.9 million and a median of $163.0 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2021 — Assets Average soared 537.74% — and 2025, when it dropped 16.43%.
- Tracing CELC's Assets Average over 5 years: stood at $88.9 million in 2021, then soared by 35.58% to $120.5 million in 2022, then jumped by 38.43% to $166.8 million in 2023, then surged by 55.32% to $259.1 million in 2024, then surged by 81.91% to $471.3 million in 2025.
- The last three Assets Average figures came in at $471.3 million (Q4 2025), $329.8 million (Q3 2025), and $200.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | 647.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 647.39 Mn |
| Dec 31, 2025 | 471.28 Mn |
| Sep 30, 2025 | 329.80 Mn |
| Jun 30, 2025 | 200.86 Mn |
| Mar 31, 2025 | 231.63 Mn |
| Dec 31, 2024 | 259.08 Mn |
| Sep 30, 2024 | 282.79 Mn |
| Jun 30, 2024 | 240.36 Mn |
| Mar 31, 2024 | 189.70 Mn |
| Dec 31, 2023 | 166.80 Mn |
| Sep 30, 2023 | 147.95 Mn |
| Jun 30, 2023 | 159.20 Mn |
| Mar 31, 2023 | 170.29 Mn |
| Dec 31, 2022 | 120.49 Mn |
| Sep 30, 2022 | 68.82 Mn |
| Jun 30, 2022 | 76.14 Mn |
| Mar 31, 2022 | 82.92 Mn |
| Dec 31, 2021 | 88.87 Mn |
| Sep 30, 2021 | 67.32 Mn |
| Jun 30, 2021 | 39.59 Mn |